refractory multiple myeloma

Related by string. Refractory Multiple Myeloma * Refractory : relapsed refractory multiple myeloma . hormone refractory prostate cancer . refractory Hodgkin lymphoma / multiples . Multiples . MULTIPLE : multiple gunshot wounds . multiple stab wounds / Myeloma . myelomas : relapsed multiple myeloma . diagnosed multiple myeloma * Relapsed Refractory Multiple Myeloma *

Related by context. All words. (Click for frequent words.) 78 relapsed refractory multiple myeloma 74 refractory AML 73 refractory chronic lymphocytic 73 refractory PTCL 72 leukemia CLL 72 metastatic renal cell carcinoma 71 castration resistant prostate cancer 71 recurrent NSCLC 71 dasatinib Sprycel ® 71 relapsed multiple myeloma 71 refractory Hodgkin lymphoma 70 refractory CLL 70 HER2 positive metastatic breast 70 dacarbazine DTIC 70 alvespimycin 70 metastatic GIST 70 stage IIIB 70 refractory cutaneous T 70 metastatic hormone refractory 69 erlotinib Tarceva ® 69 Amrubicin 69 leukemia AML 69 dacarbazine 69 evaluating Xcytrin 69 refractory NSCLC 68 carboplatin paclitaxel 68 sorafenib tablets 68 heavily pretreated 68 refractory metastatic colorectal cancer 68 oral ridaforolimus 68 MAGE A3 ASCI 68 Tarceva TM 68 platinum refractory 68 refractory CTCL 68 VELCADE melphalan 68 unresectable 68 unresectable locally advanced 68 metastatic CRC 68 axitinib 68 mRCC 68 FOLFIRI 68 refractory acute myeloid 68 cell lymphoma CTCL 68 mapatumumab 68 systemic anaplastic large 68 trastuzumab Herceptin R 67 paclitaxel Taxol ® 67 gemcitabine carboplatin 67 refractory peripheral T 67 virus HCV protease inhibitor 67 docetaxel Taxotere R 67 resistant ovarian cancer 67 Pemetrexed 67 leukemia APL 67 advanced hepatocellular carcinoma 67 vinorelbine 67 sorafenib Nexavar ® 67 gemcitabine cisplatin 67 Doxil ® 67 YONDELIS 67 refractory myeloma 67 low dose cytarabine 67 nilotinib Tasigna ® 67 Cloretazine ® 67 plus prednisone 67 PDX pralatrexate 67 CYT# potent vascular disrupting 67 refractory acute promyelocytic 67 phase IIb clinical 67 relapsed ovarian cancer 67 tanespimycin 67 cetuximab Erbitux R 67 tumors GIST 67 cisplatin gemcitabine 67 lymphoma CTCL 67 bortezomib Velcade R 66 metastatic castration resistant 66 Seliciclib 66 NSCLC 66 docetaxel chemotherapy 66 Fludara 66 IV metastatic melanoma 66 Gemzar ® 66 HGS ETR1 66 Aflibercept 66 fluoropyrimidine 66 gastrointestinal stromal tumor GIST 66 amrubicin 66 recurrent glioblastoma multiforme 66 HRPC 66 DOXIL 66 HGS ETR2 66 pegylated liposomal doxorubicin 66 telaprevir dosed 66 Phase Ib study 66 gemcitabine chemotherapy 66 imatinib Gleevec ® 66 R sorafenib tablets 66 relapsed MM 66 biologic DMARD 66 perifosine 66 metastatic RCC 66 anthracycline taxane 66 refractory indolent non 66 sorafenib Nexavar 66 Taxotere ® 66 refractory systemic ALCL 66 cutaneous T cell 66 docetaxel Taxotere ® 66 adriamycin 66 TELCYTA 66 PXD# 66 Annamycin 66 anthracyclines taxanes 66 metastatic colorectal carcinoma 66 hepatocellular carcinoma HCC 66 trabectedin 66 lintuzumab SGN 66 Bezielle 66 chlorambucil 66 relapsing multiple sclerosis 66 heavily pretreated patients 66 relapsed SCLC 66 FOLFOX6 66 stage IIIb IV 65 PEG SN# 65 hormone refractory prostate cancer 65 metastatic SCCHN 65 melphalan prednisone 65 evaluating tivozanib 65 radiation sensitizer 65 5 FU leucovorin 65 Xeloda ® 65 HuMax CD4 65 sunitinib Sutent ® 65 metastatic castrate resistant 65 PEGINTRON TM 65 pomalidomide 65 symptomatic BPH 65 metastatic HRPC 65 posaconazole 65 doxorubicin HCl liposome injection 65 paclitaxel carboplatin 65 docetaxel Taxotere 65 taxane chemotherapy 65 non squamous NSCLC 65 androgen independent 65 SCCHN 65 TELINTRA 65 B CLL 65 forodesine 65 metastatic CRPC 65 alpha folate receptor 65 Aplidin R 65 Allovectin 7 ® 65 chemotherapy cisplatin 65 capecitabine Xeloda 65 PEGylated interferon beta 1a 65 CDK cyclin dependent 65 carfilzomib 65 bevacizumab Avastin ® 65 galiximab 65 sunitinib malate 65 MGd 65 Fibrillex TM 65 Acute Myeloid Leukemia AML 65 FOLOTYN ® 65 mertansine 65 plus dacarbazine 65 EOquin TM 65 generation Hsp# inhibitor 65 paclitaxel Taxol R 65 Genasense ® 65 dasatinib Sprycel 65 metaglidasen 65 DAVANAT 65 IMGN# 65 cutaneous T 65 TORISEL 65 INSPIRE Trial Phase III 65 interferon gamma 1b 65 Cloretazine 65 metastatic colorectal cancer 65 novel emulsion formulation 65 metastatic malignant 65 dextromethorphan quinidine 64 Folfox 64 Panzem R NCD 64 Fludara ® 64 histone deacetylase HDAC inhibitor 64 valopicitabine 64 receptor tyrosine kinase inhibitor 64 pegylated interferon alpha 64 multiple myeloma MM 64 Bortezomib 64 OvaRex ® MAb 64 nab paclitaxel 64 EGFR expressing mCRC 64 proteasome inhibitor 64 AP# [003] 64 ongoing Phase 1b 64 primary hypercholesterolemia 64 Velcade bortezomib 64 Virulizin ® 64 papillary renal cell carcinoma 64 thalidomide Thalomid 64 estramustine 64 Phase #b/#a clinical 64 systemic ALCL 64 dependent kinase inhibitor 64 recurrent GBM 64 unresectable Stage III 64 CHOP chemotherapy 64 2 methoxyestradiol 64 lenalidomide Revlimid R 64 temsirolimus 64 advanced NSCLC 64 IV NSCLC 64 PegIntron 64 ZOLINZA 64 Alkeran 64 Proxinium TM 64 tumor xenograft models 64 imatinib resistant 64 interferon alfa 2b 64 Navelbine ® 64 prostate cancer HRPC 64 INCB# [001] 64 gemcitabine Gemzar 64 oblimersen 64 VEGFR2 inhibitor 64 fallopian tube carcinoma 64 refractory HL 64 PSMA ADC 64 Tarceva erlotinib 64 refractory APL 64 Voreloxin 64 interferon alfa 2a 64 GW# [003] 64 mCRC patients 64 vandetanib 64 AVASTIN 64 metastatic bladder 64 CTAP# Capsules 64 oral prodrug 64 relapsing remitting MS RRMS 64 plus dexamethasone 64 novel VDA molecule 64 cetuximab Erbitux ® 64 PREZISTA r 64 bevacizumab Avastin R 64 Peg IFN 64 irinotecan doxorubicin oxaliplatin paclitaxel 64 orally administered inhibitor 64 ZACTIMA 64 advanced metastatic renal 64 gastrointestinal stromal tumors GIST 64 bendamustine 64 OncoVEX GM CSF 64 ribavirin RBV 64 arsenic trioxide injection 64 LymphoStat B TM 64 metastatic malignant melanoma 64 evaluating REVLIMID 64 ganetespib 64 Taxotere R 64 FOLFOX regimen 64 CIMZIA ™ 64 refractory follicular lymphoma 64 IgG1 monoclonal antibody 63 huC# DM4 63 neratinib 63 glufosfamide 63 Hsp# Inhibitor 63 lumiliximab 63 elotuzumab 63 EFAPROXYN 63 Raptiva ® 63 Cutaneous T 63 pralatrexate 63 recurrent glioblastoma 63 docetaxel 63 cyclophosphamide methotrexate 63 Albuferon TM 63 phase IIb trial 63 small molecule Hedgehog 63 Irinotecan 63 alkylating agent 63 aflibercept VEGF Trap 63 COU AA 63 Hormone Refractory Prostate Cancer 63 PegIFN 63 #mg/m# [001] 63 HGS ETR1 mapatumumab 63 recurrent ovarian cancer 63 pegylated interferon alfa 2a 63 Xanafide 63 efalizumab 63 Telintra 63 unresectable stage 63 Apaziquone 63 adecatumumab 63 HGS# 63 IMiDs 63 dose escalation clinical 63 Herceptin trastuzumab 63 aplastic anemia AA 63 liposomal formulation 63 XL# anticancer compounds 63 Elotuzumab 63 Phase Ib clinical trials 63 non nucleoside inhibitor 63 Perifosine 63 myelodysplastic syndromes MDS 63 BR.# 63 TKB# 63 alpha interferons 63 Dacogen injection 63 relapsed refractory 63 PANVAC VF 63 essential thrombocythemia ET 63 remission induction 63 INC# 63 5 Fluorouracil 63 XL# XL# 63 Epothilone D 63 herpetic keratitis 63 antibody MAb 63 relapsed leukemia 63 Randomized Phase II 63 Glufosfamide 63 Peginterferon alfa 2b 63 goserelin 63 BRIM2 63 multicenter Phase III 63 refractory gout 63 lintuzumab 63 cisplatin vinorelbine 63 Genasense oblimersen sodium Injection 63 XL# XL# XL# 63 plus gemcitabine 63 oral chemotherapeutic agent 63 FOLFOX6 chemotherapy regimen 63 mitomycin 63 SPRYCEL ® 63 TEMODAL 63 demonstrated antitumor activity 63 metastatic gastric 63 R lenalidomide 63 5-FU/LV 63 plus prednisone prednisolone 63 Tamibarotene 63 HCV SPRINT 63 ponatinib 63 infliximab monotherapy 63 Hepatocellular Carcinoma HCC 63 liposomal doxorubicin 63 superficial bladder cancer 63 cytotoxic chemotherapy 63 metastatic colorectal 63 COPEGUS 63 R roscovitine 63 immunomodulatory therapy 63 PI3K/Akt pathway inhibitor 63 trastuzumab Herceptin ® 63 Stage IIIB IV 63 phase III isavuconazole 63 PEGylated anti 63 Vicinium TM 63 gastrointestinal stromal tumors 63 thymalfasin 63 K ras mutations 63 Paraplatin ® 63 dirucotide 63 histologies 63 forodesine hydrochloride 63 refractory metastatic 63 mcg albinterferon alfa 2b 63 Traficet EN 63 CR# vcMMAE 63 FOLFIRI chemotherapy 63 treatment naive genotype 63 doxorubicin cyclophosphamide 63 HuMax EGFr 63 EGFR HER2 63 docetaxel prednisone 63 5 fluorouracil leucovorin 63 anticancer compound 63 regorafenib 63 KRAS wild 63 Ixempra 62 myelofibrosis MF 62 gefitinib Iressa 62 AIR CF1 62 refractory indolent NHL 62 Perifosine KRX 62 alfa 2a 62 ribavirin therapy 62 Genasense 62 Kit CD# positive 62 Cloretazine R VNP#M 62 CEQ# 62 doublet chemotherapy 62 Platinol 62 Zorbtive TM 62 Panzem NCD 62 medullary thyroid cancer 62 irinotecan containing 62 huN# DM1 62 Hycamtin ® 62 EDEMA3 62 pegylated interferons 62 ixabepilone 62 Myelodysplastic Syndrome MDS 62 LymphoStat B belimumab 62 XL# XL# XL# XL# 62 prostate cancer CRPC 62 Peginterferon 62 Ophena TM 62 pertuzumab 62 mitoxantrone plus 62 CTA# Injection 62 infusional 5-FU/LV 62 naïve HCV 62 BRIM3 62 intravesical infusion therapy 62 Plicera 62 XELOX 62 taxane 62 Zevalin R Ibritumomab 62 AVONEX ® 62 EGFR expressing 62 TRIOLEX HE# APOPTONE HE# 62 idarubicin 62 PROSTVAC VF 62 CIMZIA TM 62 IMA# 62 talactoferrin 62 mg q#h 62 unique alkylating agent 62 MabCampath 62 pan histone deacetylase 62 non squamous 62 FOLFOX 62 MyVax R 62 hA# 62 Panzem R 62 Phase Ib II 62 hepatitis C HCV 62 ALN HPN 62 chronic lymphocytic leukemia CLL 62 R roscovitine CDK cyclin 62 non metastatic resectable 62 OPAXIO 62 hematological malignancies 62 Phase III Pivotal 62 non metastatic osteosarcoma 62 evaluating picoplatin 62 fludarabine 62 budesonide foam 62 PEGylated Fab fragment 62 Torisel 62 Quinamed 62 pediatric acute lymphoblastic 62 ELACYT 62 FOLFOX4 62 LEP ETU 62 FOLOTYN 62 nonsmall cell lung cancer 62 limiting toxicity 62 CLARITY study 62 hepatic metastases 62 dacetuzumab 62 adecatumumab MT# 62 telaprevir dosing 62 teriflunomide 62 renal cell carcinoma 62 active comparator 62 metastatic pancreatic 62 oral vancomycin 62 anti leukemic 62 PROVENGE sipuleucel T 62 HBeAg negative 62 nucleoside analog 62 romiplostim 62 asymptomatic metastatic 62 non nucleoside HCV 62 Randomized Phase 62 Aplidin 62 Nexavar sorafenib 62 treatment naïve genotype 62 paclitaxel Taxol 62 recurrent malignant glioma 62 oral nucleoside analogue 62 Pivotal Phase III 62 CYC# 62 mixed dyslipidemia 62 virus HCV infection 62 Onrigin 62 HBeAg negative patients 62 SAR# [004] 62 Telik logo TELINTRA 62 relapsed acute myelogenous 62 Zolinza 62 CANCIDAS 62 ELOXATIN 62 IMC A# 62 Camptosar ® 62 peginterferon alfa 2a Pegasys 62 omacetaxine mepesuccinate 62 basal cell carcinoma BCC 62 relapsing remitting multiple sclerosis 62 ceftazidime 62 drug pipeline TAFA# 62 Phase IIIb clinical 62 PegIFN RBV 62 Zenvia ™ 62 4mg/kg 62 G#DT 62 metastatic renal cell 62 ara C 62 EOquin 62 TYKERB 62 obatoclax 62 TLK# 62 Tanespimycin 62 investigational immunotherapy 62 Navelbine 62 Advanced Renal Cell 62 Targretin 62 Phase Ib clinical 62 splenectomized 62 visilizumab 62 castrate resistant prostate cancer 62 ER CHOP 62 mCRC 62 APOPTONE 62 resistant hormone refractory 62 PNP inhibitor 62 LEUKINE 62 PROSTVAC ® 62 Allovectin 7 62 metastatic squamous cell carcinoma 62 VNP#M 62 saline placebo 62 cell lymphoma ALCL 62 hypercalcemia 62 panitumumab Vectibix 62 peginterferon alfa 2b 62 Genasense R 62 anti EGFR antibody 62 biliary tract cancer 62 epirubicin 62 metastatic melanoma 62 NMIBC 62 cancer mCRC 62 ACTEMRA TM 62 targeting CD# 61 Daclizumab 61 generation purine nucleoside 61 ovarian carcinoma 61 Ceplene/IL-2 61 Akt inhibitor 61 esophageal candidiasis 61 vismodegib 61 Tesmilifene 61 AQ4N 61 HCV RESPOND 2 61 BAY #-# 61 assessing T DM1 61 delivers fluocinolone acetonide FA 61 phase IIb study 61 Intravenous CP 61 mycophenolate mofetil 61 Pegasys ® 61 mg/m2 dose 61 RSR# 61 standard chemotherapy regimen 61 Alocrest 61 capecitabine Xeloda R 61 recurrent metastatic 61 solid tumors 61 NEUVENGE 61 neoadjuvant 61 Tyrima 61 Copegus ribavirin 61 registrational 61 REVIVE Diabetes 61 q8h 61 bortezomib 61 resectable 61 ularitide 61 AEG# 61 RANK Ligand inhibitor 61 tamibarotene 61 oral picoplatin 61 opioid induced bowel dysfunction 61 TO AVOID PREGNANCY WHILE 61 ® lenalidomide 61 advanced carcinoid 61 leukemia ALL 61 chronic HBV infection 61 pegylated interferon alfa 61 targeted radiotherapeutic 61 luteinizing hormone releasing 61 developing Bicifadine serotonin 61 Epratuzumab 61 ACAPODENE TM 61 ALN TTR 61 AEGR 61 alefacept 61 Gliadel Wafer 61 protease inhibitor PI 61 metastatic carcinoma 61 Advanced Solid Tumors 61 TRISENOX ® 61 peg IFN 61 familial amyloidotic polyneuropathy FAP 61 refractory lymphoma 61 novel histone deacetylase 61 erlotinib 61 Taxotere chemotherapy 61 hematological cancers 61 LHRH receptor positive 61 phase Ib 61 pharmacologically active isomer 61 Phase III randomized controlled 61 cyclophosphamide doxorubicin vincristine 61 IL# PE#QQR 61 previously untreated follicular 61 mTOR inhibitor 61 HER2 negative 61 candesartan cilexetil 61 KRAS mutations occur 61 decitabine 61 Phase #/#a trial 61 Pralatrexate 61 autoantibody positive 61 advanced metastatic prostate 61 cilengitide 61 T#I mutation 61 FOLPI 61 carcinoma mCRC 61 #I TM# 61 vinca alkaloids 61 myelofibrosis polycythemia vera 61 FOLFOX chemotherapy 61 comparator arm 61 pancreatic neuroendocrine tumors 61 Diffuse Large B 61 indolent follicular non 61 cyclophosphamide chemotherapy 61 recurrent metastatic ovarian cancer 61 melphalan 61 achieved ACR# 61 Pegasys peginterferon alfa 2a 61 cisplatin chemotherapy 61 tivozanib 61 SCH # 61 lymphoid malignancies 61 pancreatic NET 61 Phenoptin 61 MYLOTARG 61 monoclonal antibody IgG1 Mab 61 Elitek 61 Relapsed Refractory 61 FluCAM 61 CRp 61 Specifid 61 malignant pleural mesothelioma 61 selective modulator 61 elacytarabine 61 BARACLUDE ® 61 Nexavar ® 61 Insegia 61 carcinoma HCC 61 Gleevec imatinib mesylate 61 Sapacitabine 61 opioid induced constipation OIC 61 DEB# 61 seliciclib 61 cell chronic lymphocytic 61 TAXOTERE R 61 Clevudine 61 mGluR5 NAM 61 rALLy clinical trial 61 metastatic androgen independent 61 gemcitabine 61 cancer neuroendocrine tumor 61 glioblastoma multiforme GBM 61 refractory DLBCL 61 EOquin TM phase 61 ZADAXIN ® 61 crizotinib PF # 61 MGCD# [001] 61 refractory chronic myeloid 61 interferon alfa 61 severe hypercholesterolemia 61 Sym# 61 receiving INTRON 61 APTIVUS r 61 abiraterone acetate 61 depsipeptide 61 pheochromocytoma 61 SCIg 61 Jevtana 61 Aurora kinase inhibitor 61 HCD# [002] 61 Imprime PGG 61 ofatumumab 61 cytarabine daunorubicin 61 fludarabine phosphate 61 multi kinase inhibitor 61 interferon beta 1a infertility 61 Saxagliptin 61 Silodosin 61 BCG refractory 61 CLL SLL 61 gemcitabine Gemzar ® 61 Ceflatonin 61 PD LID 61 CR nPR 61 multicenter Phase 61 CD# antibody [001] 61 investigational hepatitis C 61 TNF antagonists 61 omega interferon 61 Omacetaxine 61 nucleoside analogue 61 phase Ib clinical 61 PEGASYS ® 61 stage IIIb 61 adalimumab Humira 61 chemotherapy docetaxel 61 Paraplatin ® carboplatin 61 viral kinetic 61 ocular formulation 61 advanced unresectable 61 induced macular edema 61 Onrigin TM 61 oral proteasome inhibitor 61 Diabetic Macular Edema 61 dose cohort 61 Gleevec resistant 61 Vandetanib 61 AAG geldanamycin analog 61 Marqibo 61 post herpetic neuralgia PHN 61 hormone refractory metastatic prostate 61 Capecitabine 61 taxane refractory 61 octreotide implant 61 Romiplostim 61 8mg/kg 61 nonmetastatic 61 liver metastases 61 sapacitabine CYC# 61 Eli Lilly Gemzar 61 Darinaparsin 61 cediranib 61 allogeneic stem cell 61 CD# CEA 61 FUSILEV enhances 61 ZYBRESTAT 61 evaluating T DM1 61 refractory colorectal cancer 61 IV melanoma 61 bevacizumab Avastin 61 CAELYX 61 trastuzumab Herceptin 61 romidepsin 61 Hodgkin lymphoma HL 61 Platinol ® cisplatin 61 Clolar ® 61 temozolomide TMZ 61 plus DOXIL 61 Combination REOLYSIN R 60 CoFactor 60 Canvaxin TM 60 neutropenia dehydration dyspnea 60 enzastaurin 60 modified glutathione analog 60 MKC# MT 60 farletuzumab 60 cytotoxic therapy 60 HDAC Inhibitor 60 BCG refractory carcinoma 60 small lymphocytic lymphoma 60 imatinib mesylate 60 sarcoma melanoma 60 Tiuxetan 60 metformin sulfonylurea 60 mitogen activated ERK kinase 60 severe neutropenia 60 vinorelbine tartrate 60 dose cohorts 60 Virulizin R 60 TTF Therapy 60 myeloproliferative diseases 60 oxaliplatin Eloxatin 60 HQK 60 ErbB2 positive 60 evaluating satraplatin 60 Abiraterone acetate 60 JAK inhibitor 60 dosing cohort 60 Phase 2b Clinical Trial 60 pamidronate 60 Myelofibrosis 60 ThermoDox R 60 AVOREN 60 HuLuc# 60 xanthine oxidase inhibitor 60 Castration Resistant Prostate Cancer 60 Camptosar ® irinotecan 60 tyrosine kinase inhibitor TKI 60 eltrombopag 60 Lenocta TM 60 Viramidine 60 Alzhemed TM 60 splenectomized patients 60 partial remissions 60 GATTEX ® 60 TRISENOX 60 dasatinib 60 nonsquamous histology 60 Phase 2b trial 60 Solazed TM 60 INCB# [002] 60 efavirenz EFV 60 vincristine doxorubicin 60 systemic lupus erythematosus 60 CML CP 60 Arranon 60 evaluating carfilzomib 60 colorectal liver metastases 60 Marqibo TM 60 Vidaza azacitidine 60 XL# SAR# 60 myelodysplastic myeloproliferative diseases 60 GSK# [001] 60 blinded randomized placebo controlled 60 vascular disrupting agent 60 Neulasta R 60 entinostat 60 dose escalation phase 60 voriconazole 60 EURIDIS 60 Evoltra ® 60 dirucotide MBP# 60 MT# MEDI 60 untreated multiple myeloma 60 CA4P 60 perifosine KRX 60 Ceflatonin R 60 trastuzumab emtansine T DM1 60 phase IIa clinical 60 apoptosis inducer 60 methylnaltrexone bromide 60 Kahalalide F 60 Meets Primary Endpoint 60 HCV NS5B polymerase 60 R Saizen R 60 forodesine HCl 60 marketed pegylated interferons 60 Phase 2a trial 60 Combidex 60 cinacalcet HCl 60 rituximab refractory 60 potent triglyceride lowering 60 TYZEKA 60 Dementia Related Psychosis 60 pemetrexed 60 Mitoxantrone 60 taxane resistant 60 relapsed CLL 60 biochemical relapse 60 Carfilzomib 60 alkylating agents 60 Targretin capsules 60 PROVENGE 60 APTIVUS ritonavir 60 stage IIIB IV 60 Stedivaze 60 PHX# 60 flutamide 60 decompensated liver disease 60 Azedra 60 cetuximab Erbitux 60 neovascular diseases 60 HBeAg positive patients 60 sorafenib 60 BCX# 60 LUX Lung 60 selective kinase inhibitor 60 Azacitidine 60 seliciclib CYC# 60 vinca alkaloid 60 neoadjuvant treatment 60 CCR5 tropic HIV 60 peripheral sensory neuropathy 60 Raptiva R 60 Phase 2b clinical 60 histologically confirmed 60 ENMD # 60 lexidronam injection 60 tenofovir emtricitabine 60 unresectable tumors 60 lenalidomide Revlimid ® 60 tramiprosate Alzhemed TM 60 cyclophosphamide Cytoxan 60 anthracycline containing 60 antibody MT# 60 daunorubicin 60 Belimumab 60 5FU 60 following fluoropyrimidine oxaliplatin 60 diabetic neuropathic pain 60 integrin inhibitor 60 #D#C# 60 HuMax 60 Ibritumomab Tiuxetan 60 Vidaza ® 60 imetelstat 60 pancreatic adenocarcinoma 60 Ganite R 60 Motesanib 60 oral diclofenac 60 multiple myeloma 60 darinaparsin 60 Aryplase 60 Refractory Hodgkin Lymphoma 60 Lenalidomide 60 Revlimid lenalidomide 60 Palifosfamide 60 sipuleucel T 60 trastuzumab DM1 60 alpha 2b 60 Phase Ib 60 microtubule targeting 60 inhibitor RG# 60 Solazed 60 non splenectomized 60 xenograft models 60 Brentuximab Vedotin SGN 60 DU #b 60 OXi# 60 interferon therapy 60 chronic ITP patients 60 cell carcinoma RCC 60 UVIDEM 60 acid phosphatase PAP 60 AKT inhibitor 60 prior chemotherapy regimens 60 mg administered orally 60 azacitidine 60 weekly subcutaneous injections 60 Orphan Drug designations 60 Soft Tissue Sarcoma 60 LHRH antagonists 60 eribulin mesylate 60 neoadjuvant chemotherapy 60 #mg QD [002] 60 fosbretabulin 60 Flu Cy 60 dopamine partial agonist 60 JAK2 inhibitor 60 Lenocta 60 indolent NHL 60 Fludarabine 60 dosing cohorts 60 Halaven 60 Phase IIa trials 60 systemically administered 60 Thalomid ® 60 Junovan TM 60 dose escalation trial 60 phase IIb III 60 intravenous RSD# 60 RG# [001] 60 investigational monoclonal antibody 60 rALLy trial 60 IMiDs ® 60 oral clodronate 60 trastuzumab 60 EGFR TKI 60 INCB# [003] 60 TACI Ig 60 BENLYSTA belimumab 60 refractory ovarian cancer 60 mg TID 60 refractory systemic anaplastic 60 subcutaneously administered 60 squamous histology 60 CIMZIA TM certolizumab pegol 60 Carboplatin 60 Aurora kinase 60 cisplatin carboplatin 60 trastuzumab DM1 T DM1

Back to home page